(NASDAQ: VTYX) Ventyx Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Ventyx Biosciences's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast VTYX's revenue for 2026 to be $6,523,337,252, with the lowest VTYX revenue forecast at $6,523,337,252, and the highest VTYX revenue forecast at $6,523,337,252. On average, 2 Wall Street analysts forecast VTYX's revenue for 2027 to be $16,874,182,710, with the lowest VTYX revenue forecast at $184,938,140, and the highest VTYX revenue forecast at $33,563,427,280.
In 2028, VTYX is forecast to generate $29,353,239,384 in revenue, with the lowest revenue forecast at $583,266,443 and the highest revenue forecast at $58,123,212,326.